← back to the index
DV-010 urogynecology 2019

Transvaginal Mesh — 100,000 Lawsuits, $8 Billion, and a 2019 U.S. Ban

chronic-painreoperationtissue-erosionobstetrics-gynecologyurogynecology2000s2010s
Patients implanted
Hundreds of thousands of U.S. POP procedures (~tens of thousands/yr at peak)
Failure or harm
Erosion/exposure on the order of ~10% at 1 yr; >100,000 injury claims; >$8B settled
In use
~2002–2019 (transvaginal POP)
Status
Reclassified

Summary

When the U.S. Food and Drug Administration ordered Boston Scientific and Coloplast on April 16, 2019 to stop selling all surgical mesh intended for transvaginal repair of pelvic organ prolapse, the gap between the promise and the harm was already a settled scientific finding: the agency stated the manufacturers had "not demonstrated a reasonable assurance of safety and effectiveness," having "failed to demonstrate an acceptable long-term benefit of these devices compared to transvaginal surgical tissue repair without the use of mesh." The mesh had been sold for nearly two decades as a stronger, more durable fix for sagging pelvic organs. The controlled evidence showed it was no better than stitching native tissue — and considerably more dangerous.

The product was a knitted sheet of non-absorbable polypropylene, placed through the vagina to act as a hammock under a prolapsed bladder, uterus or rectum. Its central failure mode was that the implant did not stay inert. Over months and years the mesh contracted, hardened and eroded through the vaginal wall and into adjacent organs, producing a signature cluster of harms: chronic pelvic pain, dyspareunia (painful intercourse), bleeding, infection, urinary problems, organ perforation, and erosion that frequently could not be fully reversed because the mesh integrated into tissue and fragmented on removal. The FDA's own reviews put serious complications well above the "rare" reassurance physicians had been given.

The devices reached the market not through clinical proof but through the 510(k) clearance pathway, which lets a manufacturer skip pre-market testing by claiming "substantial equivalence" to an existing product — in this case an older abdominal hernia mesh and the first transvaginal kits, each in turn cleared by pointing back to a predecessor. No randomized trial of safety and effectiveness was ever required to put these implants into women. The reckoning came in two channels at once. Litigation consolidated into one of the largest mass-tort proceedings in U.S. history — more than 100,000 lawsuits against Ethicon (Johnson & Johnson), Boston Scientific, American Medical Systems, C.R. Bard, Coloplast and others, resolved for upward of $8 billion. Regulation moved more slowly: a 2008 public-health notification, a blunt 2011 reversal ("not rare"), reclassification to Class III in January 2016, and finally the 2019 stop-sale order when no maker could produce the safety data the new class demanded. Transvaginal POP mesh became the textbook case of a permanent implant cleared without proof and withdrawn only after the evidence — and the bodies — caught up.

Timeline

1996
First transvaginal sling cleared
The FDA clears the first transvaginal mesh device under 510(k) for stress urinary incontinence, citing substantial equivalence to existing surgical mesh — establishing the predicate chain.
2002
POP kits arrive
Mesh marketed specifically for transvaginal repair of pelvic organ prolapse (POP) enters wide U.S. use, cleared under 510(k) without pre-market clinical trials of safety or effectiveness.
Oct 20, 2008
First FDA Public Health Notification
Citing more than 1,000 adverse-event reports over three years, the FDA warns clinicians of complications from transvaginal mesh but calls them "rare."
Jul 13, 2011
The reversal: "not rare."
After 2,874 further reports (2008–2010), the FDA issues a Safety Communication stating serious complications are "not rare" and that mesh for POP shows no benefit over non-mesh repair.
Jan 3–4, 2012
522 study orders
The FDA orders manufacturers to conduct post-market surveillance (522) studies on POP mesh and weighs reclassification; several makers begin withdrawing POP kits rather than fund the studies.
2012–2013
Litigation consolidates
Federal MDLs in the Southern District of West Virginia under Judge Joseph R. Goodwin gather tens of thousands of pelvic-mesh claims against the major manufacturers.
Apr 2014
Reclassification proposed
The FDA proposes moving transvaginal POP mesh from Class II to Class III, requiring pre-market approval (PMA).
Jan 2016
Reclassified to Class III
The FDA finalizes the order: transvaginal POP mesh is high-risk and manufacturers must obtain PMA approval to keep marketing it.
Jul 2018
UK and Scotland pause
NHS Scotland formally halts vaginal mesh; England imposes a high-vigilance restriction (period of pause) on mesh for SUI and POP.
Apr 16, 2019
Off the U.S. market
Finding Boston Scientific's and Coloplast's PMA data inadequate, the FDA orders all transvaginal POP mesh devices to stop selling and distributing immediately.
Jan 2020
$344M verdict
A California court enters a $344 million judgment against Johnson & Johnson for deceptive mesh marketing; state attorneys-general settlements follow ($188.6M Boston Scientific; ~$117M J&J).
Jul 8, 2020
First Do No Harm
Baroness Cumberlege's UK Independent Medicines and Medical Devices Safety Review reports that pelvic mesh harm was avoidable and the system "disjointed, siloed, unresponsive and defensive."

Cleared by Resemblance, Not by Proof

The transvaginal mesh implant entered the body of medicine through a door built for spare parts. The 510(k) pathway, created by the 1976 Medical Device Amendments, allows a device to reach market without clinical trials if its maker can show it is "substantially equivalent" to a product already on sale. Polypropylene surgical mesh had long been used in abdominal hernia repair; transvaginal kits for stress incontinence were cleared by pointing to that predicate; and POP kits, from roughly 2002, were cleared by pointing to the incontinence slings. Each clearance leaned on the one before it, so that no link in the chain ever had to demonstrate that a permanent plastic mesh, knitted through the vaginal wall to suspend a prolapsed organ, was safe and effective for that purpose. The marketing claim was durability: native-tissue repair, which simply reinforces the patient's own weakened structures with sutures, has a meaningful recurrence rate, and mesh was sold as the stronger, longer-lasting answer. The substantial-equivalence finding asserted that the new use was no riskier than the old. It was a regulatory inference, not an experimental result.

The Implant That Would Not Stay Inert

The premise that a synthetic mesh would sit quietly as a passive scaffold proved wrong in a specific and damaging way. Polypropylene mesh in the pelvic floor provokes a chronic foreign-body response; the implant contracts and stiffens as scar tissue forms around it, and in a substantial fraction of women it erodes — working its way through the thin vaginal wall (exposure) or into the bladder, urethra or bowel (extrusion). The resulting harm cluster is distinctive: chronic pelvic and groin pain, dyspareunia severe enough to end sexual function, recurrent infection, abnormal bleeding, fistula, and urinary dysfunction. The FDA's 2011 communication put exposure rates on the order of 10 percent within twelve months and judged serious complications "not rare," directly contradicting the 2008 "rare" framing. The cruelest feature was irreversibility: because the mesh integrates into tissue and fragments when pulled, complete removal is technically difficult and often impossible, so a single outpatient implant could commit a woman to multiple revision surgeries and permanent pain. The signal accumulated in MAUDE adverse-event reports — over a thousand by 2008, nearly three thousand more by 2010 — years before any device left the market.

Two Reckonings, One Slow and One Fast

The accounting arrived through litigation long before regulation closed the question. From 2012 the federal courts consolidated pelvic-mesh claims into multidistrict litigation before Judge Joseph R. Goodwin in the Southern District of West Virginia — eventually more than 100,000 cases against Ethicon (Johnson & Johnson), Boston Scientific, American Medical Systems, C.R. Bard, Coloplast and others. Juries returned multi-million-dollar verdicts; American Medical Systems alone reserved more than $2.6 billion; Boston Scientific paid roughly $189 million to 47 states and the District of Columbia over deceptive marketing; total settlements and verdicts across manufacturers exceeded $8 billion. The regulatory channel moved at a different pace: the 2011 "not rare" finding, the 2012 study orders most makers declined to fund, the January 2016 reclassification to high-risk Class III, and finally the April 16, 2019 order pulling Boston Scientific's and Coloplast's remaining POP devices when their pre-market data failed the new standard. Abroad, the reckoning was sharper and more institutional: Scotland suspended mesh in 2018 and England imposed a pause, and in July 2020 Baroness Cumberlege's First Do No Harm review found the harm avoidable and the system defensive. The device was condemned by its own evidence — the trials that were never required, run in retrospect by the courts.

Contributing Factors

01
Predicate-chain clearance without trials
The 510(k) substantial-equivalence pathway let each generation of mesh reach market by resembling the last, so a permanent transvaginal implant for prolapse was sold to hundreds of thousands of women without a single required safety-and-effectiveness trial. Regulatory clearance was mistaken, by clinicians and patients alike, for clinical proof.
02
A "stronger fix" claim that ignored the host response
The durability premise treated polypropylene as an inert scaffold and ignored that the body contracts, scars around and rejects the implant. A marketing story about mechanical strength substituted for a biological account of how a foreign body behaves in living pelvic tissue over years.
03
Irreversibility designed in, not disclosed
Because the mesh integrates into tissue and fragments on removal, a complication was frequently a life sentence of revision surgery and pain rather than a fixable event. The device's permanence was sold as a benefit and never reframed as the dominant risk it was.
04
A safety signal downgraded, then reversed too late
The FDA's 2008 notification labeled complications "rare," anchoring physician reassurance, only for the 2011 update to call them "not rare." Three years of "rare" framing, while adverse-event reports tripled, let implantation continue at scale on a characterization the agency itself would retract.
05
Litigation as the de facto evidence base
The randomized comparison the clearance pathway never demanded was effectively run in the courts, where discovery and MDL consolidation produced the documentary record — and the $8-billion-plus price — that pre-market regulation had skipped.

Aftermath

The material consequence was a market erased and a bill exceeding $8 billion: transvaginal POP mesh is no longer sold in the United States, Boston Scientific and Coloplast were ordered to withdraw it in 2019, and the manufacturers paid more than 100,000 claimants through settlements and verdicts, with American Medical Systems reserving over $2.6 billion alone. The durable ripple was regulatory and international. In the U.S., the case became Exhibit A in the long argument that the 510(k) pathway is unfit for high-risk permanent implants, feeding pressure for stricter device oversight. In the United Kingdom, it produced an institutional reckoning U.S. regulation never matched: Scotland's 2018 suspension, England's pause, and the July 2020 First Do No Harm review, which condemned a healthcare system that was "disjointed, siloed, unresponsive and defensive" toward women reporting harm and recommended a patient-safety commissioner and a register of implants. What remains is the distinction the FDA itself drew but the public rarely hears — that mesh slings for stress urinary incontinence stayed on the market while transvaginal mesh for prolapse was withdrawn — and a generation of women living with non-removable implants. Transvaginal mesh became the byword for a device cleared by resemblance and recalled by reclassification: proof deferred until the courtroom, with the patients as the trial.

Lessons

  1. Treat "substantially equivalent" as a regulatory convenience, not a safety finding — for any permanent implant, demand the trial that clearance by resemblance skips, and never read FDA clearance as proof of effectiveness.
  2. When a device is irreversible, weight the worst-case complication, not the average outcome: a 10-percent erosion rate on an implant that cannot be fully removed is a different risk than a 10-percent rate on a procedure you can redo.
  3. Distrust the word "rare" until adverse-event counts are denominated against implant volume and tracked over years; a "rare" label that has to be retracted is a signal the surveillance was too weak from the start.
  4. Compare a new device against the existing standard of care, not against nothing — the finding that mesh offered no benefit over native-tissue repair should have been a pre-market requirement, not a post-market discovery.
  5. Build the patient-report channel before the harm scales: the UK review's core lesson is that a system which is defensive toward people reporting injury converts a fixable signal into a decade-long catastrophe.

References